⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 8, 2025

Figure S9 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Zahra Davoudi Thomas S. Dexheimer Nathan P. Coussens Thomas Silvers Raymond G. Fox Samantha B. Kemp Poorva Juneja Joel Morris Melinda G. Hollingshead Naoko Takebe James H. Doroshow Beverly A. Teicher

View Full Paper

Ask AI

Bookmark

Share

Key Points

Combination therapy leads to increased activity in patient-derived spheroids, showcasing the potential for treating various cancers.
Key evidence includes the evaluation of batoprotafib combined with nintedanib in multicell-type tumor spheroids, indicating promising outcomes.
Analysis using multicell-type tumor spheroids explores how these combinations can affect cancer treatment strategies.
Findings suggest potential new avenues for targeted therapy, emphasizing the need for further research across cancer types.

Implication

Combination therapy shows activity of RAS pathway inhibitors in spheroids with oncogenic KRAS variants, highlighting potential effectiveness.

Abstract

Figure S9. Combination activity of batoprotafib with nintedanib in multicell-type tumor spheroids.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3b84 https://doi.org/10.1158/2767-9764.30304675

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S11 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
2Figure S12 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
3Figure S4 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
4Figure S15 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
5Figure S10 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025